https://www.selleckchem.com/products/th1760.html
Treatment options for outpatients with COVID-19 could reduce morbidity and prevent SARS-CoV-2 transmission. In this randomized, double-blind, three-arm (111) placebo-equivalent controlled trial conducted remotely throughout the United States, adult outpatients with laboratory-confirmed SARS-CoV-2 infection were recruited. Participants were randomly assigned to receive hydroxychloroquine (HCQ) (400mg BID x1day, followed by 200mg BID x9days) with or without azithromycin (AZ) (500mg, then 250mg daily x4days) or placebo-equivalent (ascorbic
Like
Comment
Share
